2.52

3.08% -0.08

After Hours: 2.57 0.05 +1.98%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $2.52, with a volume of 5.81M. It is down -3.08% in the last 24 hours and up +5.00% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$2.60

Open:

$2.66

24h Volume:

5.81M

Relative Volume:

0.48

Market Cap:

$1.00B

Revenue:

$241.53M

Net Income/Loss:

$-389.92M

P/E Ratio:

-2.0488

EPS:

-1.23

Net Cash Flow:

$-323.54M

1W Performance:

+6.78%

1M Performance:

+5.00%

6M Performance:

+13.00%

1Y Performance:

-52.81%

1-Day Range:

$2.50

$2.68

1-Week Range:

$2.42

$2.725

52-Week Range:

$1.6385

$6.09

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

838

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	2.52	1.03B	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-15-25	Downgrade	Goldman	Neutral → Sell
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

02:32 AM

Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn

02:32 AM

Feb 11, 2026

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - The Manila Times

Feb 11, 2026

Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative

Feb 11, 2026

Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire

Feb 11, 2026

Feb 07, 2026

Market Wrap: Will Iovance Biotherapeutics Inc benefit from green energy policiesCPI Data & Expert Curated Trade Setups - baoquankhu1.vn

Feb 07, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility - Yahoo Finance

Feb 07, 2026

Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness - Yahoo Finance

Feb 07, 2026

Iovance’s Amtagvi Data and Valuation Gap Refocus Investor Attention - Yahoo Finance

Feb 07, 2026

Feb 06, 2026

Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive? - Sahm

Feb 06, 2026

Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure - Insider Monkey

Feb 06, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Feb 06, 2026

Feb 05, 2026

Melanoma cell therapy shows 52% response when used earlier - stocktitan.net

Feb 05, 2026

Iovance Biotherapeutics Announces Promising Real-World Data for Amtagvi® in Advanced Melanoma Treatment - Quiver Quantitative

Feb 05, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewswire

Feb 05, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Feb 05, 2026

Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA) - The Globe and Mail

Feb 05, 2026

Feb 04, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation As It Transitions To Commercial Stage With First Product Launch Plans - Sahm

Feb 04, 2026

Feb 03, 2026

Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN

Feb 03, 2026

Feb 02, 2026

Former Iovance CEO Maria Fardis lands at AirNexis with $200 millionBizwomen - The Business Journals

Feb 02, 2026

She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals

Feb 02, 2026

Performance Recap: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Opening Moves & Capital Efficiency Focused Strategies - baoquankhu1.vn

Feb 02, 2026

Feb 01, 2026

Trade Recap: Whats the beta of Iovance Biotherapeutics Inc stockOptions Play & Real-Time Sentiment Analysis - baoquankhu1.vn

Feb 01, 2026

Jan 30, 2026